The Effects of Mindfulness-based Stress Reduction in Interstitial Cystitis Patients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03722992 |
|
Recruitment Status :
Completed
First Posted : October 29, 2018
Last Update Posted : July 23, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Interstitial Cystitis | Other: MBSR | Not Applicable |
Interstitial cystitis (IC), or Painful Bladder Syndrome (PBS) is a debilitating condition of the bladder that is estimated to affect 3-8 million women in the United States. The pathophysiology of the disease is poorly understood, and thus treatment modalities and treatment efficacy vary widely. Lately, much attention has shifted toward investigating how the bladder 'environment' differs amongst women with IC compared to those who do not suffer from IC.
Mindfulness-based stress reduction (MBSR), a complementary alternative medicine (CAM)-based therapy, is a standardized program including components of meditation and yoga. Recent studies show that MBSR improves symptoms in the IC patient population.
The purpose of this study is to compare measurable differences in the urinary microbiome among women with IC before and after MBSR treatment.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 14 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | The Effects of Mindfulness-based Stress Reduction on the Urinary Microbiome in Patients With Interstitial Cystitis/Painful Bladder Syndrome |
| Actual Study Start Date : | March 7, 2019 |
| Actual Primary Completion Date : | January 15, 2020 |
| Actual Study Completion Date : | March 15, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Mindfulness Cohort
Mindfulness-based stress reduction (MBSR) treatment group
|
Other: MBSR
Guided yoga and meditation practices |
- Difference in the urinary microbiome before and after MBSR treatment [ Time Frame: Before intervention and after completion of the intervention, up to 9 weeks ]Urinary microbiome sequencing analysis will be performed by Resphera Biosciences Laboratory
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adults 18 years of age or older
- English-speaking
- Established patient of Cincinnati Urogynecology Associates, TriHealth Inc.
- Current diagnosis of IC/PBS, as defined by the American Urological Association (AUA)
- Negative urinalysis or urine culture within 2 months of enrollment
- Currently undergoing first or second-line treatment for IC, as defined by the AUA
- Willingness to participate in study
Exclusion Criteria:
- Non-English speaking
- Unwillingness to participate in study
- Pregnancy or breastfeeding
- Physical or mental impairment that would affect the subject's ability to participate in the MBSR treatment, including patients with Dementia, Parkinsonism, or those who have impaired mobility or hearing
- Current or expected prolonged catheterization
- Expected travel or surgery that would hinder the ability to attend all eight MBSR sessions
- Undergoing third-, fourth-, fifth-, or sixth-line treatment for IC as defined by the AUA
- Subjects on antibiotics currently or prior use within one week of consenting
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03722992
| United States, Ohio | |
| TriHealth - Cincinnati Urogynecology Associates | |
| Cincinnati, Ohio, United States, 45220 | |
| Principal Investigator: | Rachel Pauls, MD | TriHealth - Cincinnati Urogynecology Associates |
| Responsible Party: | TriHealth Inc. |
| ClinicalTrials.gov Identifier: | NCT03722992 |
| Other Study ID Numbers: |
18-056 |
| First Posted: | October 29, 2018 Key Record Dates |
| Last Update Posted: | July 23, 2020 |
| Last Verified: | November 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Cystitis Cystitis, Interstitial Urinary Bladder Diseases Urologic Diseases |

